Strides buys soft gel capsule facility in U.S.

Strides says a new soft gel facility it has bought in the U.S. will give it much more capacity and compliments its other facilities. (Pixabay)

Strides Pharma has picked up a soft gel manufacturing facility in the U.S. from Micelle BioPharma for very little but intends to invest in it. 

The Indian drugmaker said today that it bought the Riviera Beach, Florida facility for $500,000 but will invest another $10 million to add other capabilities. It said it is one of the very few manufacturing plants in the U.S. with a soft gel capsule suite for formulations with containment. It also said it has the only  FDA  approved integrated manufacturing‐packaging SGC facility in the U.S.

RELATED: FDA investigators discover key Strides Pharma quality records in shredding room

Strides, which now has eight formulation facility globally, the facility has passed several U.S. inspections.

That is not true of all of Strides' other facilities. The FDA last month issued a warning letter to one of Strides' facilities in India. The agency said the drug testing records at a Strides Pharma plant in a shredding room, indicating the facilities had been data integrity issues, as well as other problems. 

Suggested Articles

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

Biocon’s key biosimilars plant in Bengaluru, India, has gotten mixed reviews from the FDA and has now received a Form 483 with five observations.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?